Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478646PMC
http://dx.doi.org/10.1038/s41375-021-01269-3DOI Listing

Publication Analysis

Top Keywords

single vhh-directed
4
vhh-directed bcma
4
bcma car-t
4
car-t cells
4
cells remission
4
remission relapsed/refractory
4
relapsed/refractory multiple
4
multiple myeloma
4
single
1
bcma
1

Similar Publications

Natural killer (NK) cells are promising alternatives for the production of "off-the-shelf" CAR products, posing a lower risk of cytokine release syndrome (CRS) than CAR-T cells. We synthesized four single VHH-directed anti-BCMA CARs, incorporating various intracellular regions (2B4 versus CD28) and hinge domains (CD28 versus IgG1) and ectopically producing IL-15. NK cells derived from peripheral blood (PB) were expanded ex vivo by K562-mbIL21 feeder cells.

View Article and Find Full Text PDF

Background: Adoptive cell therapy with engineered T cells expressing chimeric antigen receptors (CARs) originated from antibodies is a promising strategy in cancer immunotherapy. Several unsuccessful trials, however, highlight the need for alternative conventional binding domains and the better combination of costimulatory endodomains for CAR construction to improve the effector functions of the engineered T cells. Camelid single-domain antibodies (VHHs), which are the smallest single domain antibodies, can endow great targeting ability to CAR-engineered T cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!